Mizuho analyst Graig Suvannavejh downgraded Alector (ALEC) to Neutral from Outperform with a price target of $2.50, down from $9. Following the negative Phase 2 INVOKE-2 results for AL002, the firm removed AL002 and the AbbVie (ABBV) collaboration from the model. With the next major stock catalyst not expected until the end of 2025 or Q1 of 2026, “poor visibility on news flow that could move the shares materially higher suggests a limited opportunity for stock outperformance,” the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC: